journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Psychopharmacology

journal
https://www.readbyqxmd.com/read/30346444/corrigendum
#1
(no author information available yet)
[This corrects the article DOI: 10.1177/2045125318782694.].
November 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/30344998/are-structural-brain-changes-in-schizophrenia-related-to-antipsychotic-medication-a-narrative-review-of-the-evidence-from-a-clinical-perspective
#2
REVIEW
Stephen M Lawrie
Some observational studies and literature reviews suggest that antipsychotic drug use is associated with loss of grey or white matter in patients with schizophrenia, whereas others have contradicted this finding. Here, I summarize and critique the available evidence and put it in the context of clinical practice. This narrative review pools evidence from observational and experimental studies in humans and animals on the relationship between antipsychotic medication use and brain structure and function in patients with schizophrenia...
November 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/30344997/the-acute-efficacy-of-antipsychotics-in-schizophrenia-a-review-of-recent-meta-analyses
#3
REVIEW
Peter M Haddad, Christoph U Correll
Schizophrenia is the eighth leading cause of disability worldwide in people aged 15-44 years. Before antidopaminergic antipsychotics were introduced in the 1950s, no effective medications existed for the treatment of schizophrenia. This review summarizes key meta-analytic findings regarding antipsychotic efficacy in the acute treatment of schizophrenia, including clozapine in treatment-resistant patients. In the most comprehensive meta-analysis of randomized controlled trials conducted in multi-episode schizophrenia, antipsychotics outperformed placebo regarding total symptoms, positive symptoms, negative symptoms, depressive symptoms, quality of life and social functioning...
November 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/30344996/real-world-effectiveness-of-long-acting-antipsychotic-treatments-in-a-nationwide-cohort-of-3957-patients-with-schizophrenia-schizoaffective-disorder-and-other-diagnoses-in-quebec
#4
Emmanuel Stip, Jean Lachaine
Background: Long-acting injectable antipsychotics (LAI-AP) for patients with schizophrenia (SCZ) have saved significant healthcare costs. However, the cost effectiveness of LAI-AP for patients with other mental disorders has yet to be established. The goal of this study was to evaluate the impact of early initiation of LAI-AP medications on healthcare resource utilization (HRU). Drawing on the Quebecois universal healthcare program (RAMQ), we conducted a nationwide prospective cohort study of LAI-AP under real-world conditions...
November 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/30210778/tarc-turkish-aripiprazole-consensus-report-aripiprazole-use-and-switching-from-other-antipsychotics-to-aripiprazole-consensus-recommendations-by-a-turkish-multidisciplinary-panel
#5
REVIEW
Baybars Veznedaroglu, Nesrin Dilbaz, Ozcan Uzun, Erdal Isik
In this review, we have attempted to share our 10 years' clinical experience with aripiprazole use and switching from other antipsychotics to aripiprazole. There are various reasons for switching, including a partial or complete lack of efficacy, adverse side effects, and partial or noncompliance with medication. Aripiprazole has some unique receptor-binding qualities that provides some advantages over other antipsychotics in certain clinical situations. We have covered potential clinical scenarios for aripiprazole use as a single agent and switching from other agents in inpatient and outpatient settings...
October 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/30181867/epidemiology-and-risk-factors-for-bipolar-disorder
#6
REVIEW
Tobias A Rowland, Steven Marwaha
Bipolar disorder is a multifactorial illness with uncertain aetiology. Knowledge of potential risk factors enables clinicians to identify patients who are more likely to develop bipolar disorder, which directs further investigation, follow up and caution when prescribing. Ideally, identifying directly causative factors for bipolar disorder would enable intervention on an individual or population level to prevent the development of the illness, and improve outcomes through earlier treatment. This article reviews the epidemiology of bipolar disorder, along with putative demographic, genetic and environmental risk factors, while assessing the strength of these associations and to what extent they might be said to be 'causative'...
September 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/30181866/haloperidol-decanoate-long-acting-injection-hdlai-results-of-a-1-year-mirror-image-study
#7
Shubhra Mace, Olubanke Dzahini, Maria O'Hagan, David Taylor
Background: We sought to determine clinical outcomes of the prescribing of haloperidol decanoate long-acting injection (HDLAI) at 1 year. Method: A 1-year mirror-image study of 84 inpatients initiated on HDLAI. Admissions and bed days in the year preceding HDLAI were compared with the year after initiation. Predictors for discontinuation were evaluated. Results: At 1 year, 33% of patients remained on treatment. Patients starting HDLAI because of nonadherence were more likely to stop treatment [relative risk (RR) 1...
September 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/30065814/dilemmas-in-the-treatment-of-early-onset-first-episode-psychosis
#8
REVIEW
Daniel Hayes, Marinos Kyriakopoulos
Early-onset first-episode psychosis (EOP) is a severe mental disorder that can pose a number of challenges to clinicians, young people and their families. Its assessment and differentiation from other neurodevelopmental and mental health conditions may at times be difficult, its treatment may not always lead to optimal outcomes and can be associated with significant side effects, and its long-term course and prognosis seem to be less favourable compared with the adult-onset disorder. In this paper, we discuss some dilemmas associated with the evaluation and management of EOP and propose approaches that can be used in the clinical decision-making process...
August 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/30065813/predicting-rehospitalization-in-patients-treated-with-antipsychotics-a-prospective-observational-study
#9
Heshu Abdullah-Koolmees, Helga Gardarsdottir, Lotte A Minnema, Kamjar Elmi, Lennart J Stoker, Judith Vuyk, Laurette E Goedhard, Toine C G Egberts, Eibert R Heerdink
Background: Prediction of rehospitalization in patients treated with antipsychotics is important for identifying patients in need of additional support to prevent hospitalization. Our aim was to identify factors that predict rehospitalization in patients treated with antipsychotics at discharge from a psychiatric hospital. Methods: Adult patients suffering from schizophrenia, psychotic or bipolar I disorders who had been hospitalized in a psychiatric hospital for ⩾7 days and were treated with oral antipsychotics at discharge were included...
August 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29977520/psychiatric-manifestations-in-wilson-s-disease-possibilities-and-difficulties-for-treatment
#10
REVIEW
Tomasz Litwin, Petr Dusek, Tomasz Szafrański, Karolina Dzieżyc, Anna Członkowska, Janusz K Rybakowski
Wilson's disease (WD) is an inherited metabolic disorder related to disturbances of copper metabolism, and predominantly presents with liver and neuropsychiatric symptoms. In most cases it can be successfully treated with anti-copper agents, and both liver function and neuropsychiatric symptoms typically improve. Treatment guidelines for WD include recommendations for anti-copper treatment as well as for the treatment of liver failure symptoms. Recently, recommendations for treatment of the neurological symptoms of WD have also been proposed...
July 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29977519/amisulpride-augmentation-of-clozapine-for-treatment-refractory-schizophrenia-a-double-blind-placebo-controlled-trial
#11
Thomas R E Barnes, Verity Leeson, Carol Paton, Louise Marston, David P Osborn, Raj Kumar, Patrick Keown, Rameez Zafar, Khalid Iqbal, Vineet Singh, Pavel Fridrich, Zachary Fitzgerald, Hemant Bagalkote, Peter M Haddad, Mariwan Husni, Tim Amos
Background: A second antipsychotic is commonly added to clozapine to treat refractory schizophrenia, notwithstanding the limited evidence to support such practice. Methods: The efficacy and adverse effects of this pharmacological strategy were examined in a double-blind, placebo-controlled, 12-week randomized trial of clozapine augmentation with amisulpride, involving 68 adults with treatment-resistant schizophrenia and persistent symptoms despite a predefined trial of clozapine...
July 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29977518/rethinking-the-spectrum-of-mood-disorders-implications-for-diagnosis-and-management-proceedings-of-a-symposium-presented-at-the-30th-annual-european-college-of-neuropsychopharmacology-congress-4-september-2017-paris-france
#12
REVIEW
Roger S McIntyre, Allan H Young, Peter M Haddad
The simultaneous occurrence of manic and depressive features has been recognized since classical times, but the term 'mixed state' was first used by Kraepelin at the end of the 19th century. From the 1980s, until the advent of the Diagnostic and Statistical Manual of Mental Disorders , fifth edition (DSM-5), psychiatric disorders were classified using a categorical approach. However, it was recognized that such an approach was too rigid to encompass the range of symptomatology encountered in clinical practice...
June 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29854396/switching-and-augmentation-strategies-for-antipsychotic-medications-in-acute-phase-schizophrenia-latest-evidence-and-place-in-therapy
#13
REVIEW
Kotaro Hatta, Naoya Sugiyama, Hiroto Ito
In terms of effectiveness of antipsychotics in schizophrenia, discrepancy often exists between results from double-blind randomized controlled trials and observations in emergency or acute-phase clinical practice. For instance, the antipsychotic switching strategy is not always applicable in emergency or acute-phase situations, and augmentation of another antipsychotic is occasionally done instead. In this review, we discuss strategies for early nonresponse to an antipsychotic drug such as switching and augmentation from the perspective of emergency and acute-phase treatment...
June 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29854395/naming-the-drugs-we-use-neuroscience-based-nomenclature-a-helpful-innovation
#14
EDITORIAL
Sue Wilson
No abstract text is available yet for this article.
June 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29713452/challenges-of-the-pharmacological-management-of-benzodiazepine-withdrawal-dependence-and-discontinuation
#15
REVIEW
Dimy Fluyau, Neelambika Revadigar, Brittany E Manobianco
Background: Benzodiazepines (BZDs) are among the most prescribed sedative hypnotics and among the most misused and abused medications by patients, in parallel with opioids. It is estimated that more than 100 million Benzodiazepine (BZD) prescriptions were written in the United States in 2009. While medically useful, BZDs are potentially dangerous. The co-occurring abuse of opioids and BZD, as well as increases in BZD abuse, tolerance, dependence, and short- and long-term side effects, have prompted a worldwide discussion about the challenging aspects of medically managing the discontinuation of BZDs...
May 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29713451/effectiveness-of-paliperidone-long-acting-injection-in-clinical-practice
#16
Paul Nicholas Deslandes, Elan Haf Ward, Kathryn Norris, Robert David Sewell
Background: The efficacy of the long-acting injectable formulation of the antipsychotic paliperidone (paliperidone palmitate) has been investigated in randomized controlled trials. Due to the nature of study designs, these may not be representative of usual clinical practice. The aim of this study was to assess the clinical effectiveness of the long-acting injectable antipsychotic paliperidone palmitate using treatment continuation at 1 year as an outcome. Methods: Patients were initiated on paliperidone palmitate prior to December 2014 in a single health board in Wales (UK)...
May 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29607005/the-antipsychotic-landscape-dopamine-and-beyond
#17
REVIEW
Paul D Morrison, Robin M Murray
Until recently, the actions of antipsychotic and pro-psychotic drugs have largely been evaluated in the framework of neuronal doctrine - namely, that neurons communicate by releasing transmitters, and that psychiatric disorders are caused by neurotransmitter imbalances. Moreover, the majority of studies have focused on single transmitter systems - neglecting the fact that in the nervous system, different transmitter systems work in concert and impact on not only their immediate receptors but also downstream pathways that shape structural plasticity...
April 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29607004/a-prospective-year-long-follow-up-of-lurasidone-use-in-clinical-practice-factors-predicting-treatment-persistence
#18
Ian J Osborne, Shubhra Mace, David Taylor
Background: Our aim was to follow up patients prescribed lurasidone over 1 year to determine factors predicting treatment persistence. Methods: We used noninterventional, observational, prospective follow up of patients consecutively prescribed lurasidone in a large inner-city NHS mental health trust. We also performed retrospective analysis of outcomes from patient case notes. Results: Data were available for 69 patients consecutively prescribed lurasidone, of whom three (4%) were lost to follow up...
April 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29492258/benzodiazepine-prescription-in-ontario-residents-aged-65-and-over-a-population-based-study-from-1998-to-2013
#19
Simon J C Davies, Binu Jacob, David Rudoler, Juveria Zaheer, Claire de Oliveira, Paul Kurdyak
Background: Although commonly used in anxiety and insomnia, recent guidelines recommend caution when prescribing benzodiazepines in the elderly. Here we examined rates of benzodiazepine prescribing to older adults in Ontario, Canada from 1998 to 2013 and impact of legislation that made prescribing regulations more strict. Method: Annual benzodiazepine prescription rates for Ontario residents aged 65 and over were examined using the Ontario Drug Benefit database which captures all publicly funded prescriptions...
March 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29492257/alternatives-to-ketamine-in-depression-state-of-the-art-and-future-perspectives
#20
EDITORIAL
Luke A Jelen, Sinead King, James M Stone
No abstract text is available yet for this article.
March 2018: Therapeutic Advances in Psychopharmacology
journal
journal
43489
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"